NCT04071652已完成不适用
MATTERS Study - Mistral Percutaneous Tricuspid Valve Repair FIM Study
Mitralix6 个研究点 分布在 1 个国家目标入组 17 人开始时间: 2017年8月8日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 17
- 试验地点
- 6
- 主要终点
- Safety: Acute safety. Rate of device related SAE
研究概览
简要总结
The Mistral is an investigational device intended for percutaneous trans-catheter repair in high risk for surgery individuals suffering from functional Tricuspid Regurgitation (TR).
The device system is to be used only in accordance with the approved Investigational Plan on subjects who have signed an informed consent form. Device use is limited to the approved study investigators.
详细描述
The study is designed to clinically demonstrate device acute safety and technical performance (Primary Endpoints) along with longer FU device safety and effectiveness evaluation (Secondary Endpoint).
The main objectives of the study are :
- Evaluate the Acute safety of the implanted Mistral device post procedure and at 30 day follow up period.
- Evaluate the long term Safety of the device.
- Demonstrate effectiveness of the Mistral device in reducing TR.
Primary endpoints:
- Safety: Acute safety. Rate of device related SAE including device related mortality, stroke, MI, cardiac tamponade, surgery for failed percutaneous repair and non-elective cardiovascular surgery to treat an adverse event. At discharge and 30 days.
- Performance: Mistral Implantation rate of technical success (defined as successful device implantation with grasped chords from at least two leaflets.).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject has given signed study Informed Consent for participation prior to procedure.
- •Subject is ≥ 18 years of age or legal age in host country
- •Subject is willing and able to comply with all required follow-up evaluations
- •Genders eligible for the study: Both genders
- •Subject has TR of grade 3+ or more
- •Subject has left ventricular ejection fraction (LVEF) >20 %
- •Subject is of functional class 2 or more (NYHA)
- •The subject is high risk to undergo TV surgery as assessed and consented by a cardiac surgeon and an interventional cardiologist at the site (center heart team), and according to ESC/EACTS guidelines on the management of valvular heart disease.
- •Patients with Jugular and/or Femoral veins enabling catheterization with 12Fr catheters
- •Life expectancy ≥ 1 year
排除标准
- •Tricuspid Stenosis >mild
- •Tricuspid Subvalvular calcification or calcification of the chordae.
- •Subject has a history of a cerebral vascular accident (CVA) or transient ischemic attack (TIA) within the past 3 months.
- •Subject has a history of a myocardial infarction (MI) in the past 3 months
- •Subject has had a percutaneous interventional or other invasive cardiac or peripheral procedure ≤ 7 days of the index procedure
- •Subject has a history of, or has active endocarditis
- •Subject has echocardiographic evidence of intra-cardiac mass, thrombus, vegetation or soft-mobile deposits
- •Subject is in acute pulmonary edema.
- •Subject has hemodynamic instability requiring inotropic or mechanical support.
- •Subject has a known hypersensitivity or contraindication to anticoagulant or antiplatelet medication
- •Subject has renal insufficiency as evidenced by a serum Creatinine > 3.0mg/dL.
- •Subject has ongoing infection or sepsis
- •Subject has blood dyscrasias (leukopenia, acute anemia, thrombocytopenia, history of bleeding diathesis, or coagulopathy)
- •Subject has an active peptic ulcer or has had gastrointestinal (GI) bleeding within the past 3 months prior to the index procedure
- •Subject requires emergency surgery for any reason
- •Subject has a known allergy to Nitinol alloys, 316L\304 stainless steel.
- •Pregnant or lactating women.
- •Patients being dependent upon the sponsor or upon the investigator or upon the investigational site.
- •Subject has a known contrast media allergy
- •Presence of high degree atrio-ventricular block (2nd or 3rd degree A-V block), or the presence of tri-fascicular block
- •According to investigator on site the patient is suffering from a severe end stage disease (e.g. malignancy, severe pulmonary disease, liver disease, renal failure) and has a life expectancy of less than 1 year.
- •Contraindication for treatment with dual antiplatelet therapy for at least 3 months
- •Contraindication for TEE including trans-gastric views.
结局指标
主要结局
Safety: Acute safety. Rate of device related SAE
时间窗: At 30 days post procedure
including device related mortality, stroke, MI, cardiac tamponade, surgery for failed percutaneous repair and non-elective cardiovascular surgery to treat an adverse event
Performance: Mistral Implantation rate of technical success
时间窗: Procedure
defined as successful device implantation with grasped chords from at least two leaflets
次要结局
- Effectiveness: NYHA class (categorization of heart failure extent)(at 24 months post procedure)
- Effectiveness: TR Grade reduction(at 24 months post procedure)
- Safety: Rate of device related SAE(at 24 months post procedure)
- Effectiveness: 6MWT distance(at 24 months post procedure)
- Effectiveness: KCCQ (Kansas City Cardiomyopathy Questionnaire)(at 24 months post procedure)
研究者
研究点 (6)
Loading locations...
相似试验
已完成
不适用
MATTERS II - Mistral Percutaneous Tricuspid Valve Repair FIM StudyTricuspid Valve RegurgitationNCT04073979Mitralix9
招募中
不适用
Mistral Percutaneous Tricuspid Valve Durable Repair Pivotal StudyTricuspid Valve RegurgitationNCT05767645Mitralix75
已完成
不适用
MERIT Study - Mistral Percutaneous Mitral Valve Repair FIM StudyMitral Valve RegurgitationNCT02948231Mitralix4
尚未招募
不适用
Confirmatory Clinical Study of Treating Tricuspid Regurgitation With K-Clip TM Transcatheter Annuloplasty SystemTricuspid RegurgitationNCT05173233Shanghai Huihe Medical Technology Co., Ltd67
进行中（未招募）
不适用
A First in Human Study for the Versa Device for Tricuspid RegurgitationTricuspid RegurgitationNCT06368401Versa Vascular, Inc10